Dermatology Times, April 2025 (Vol. 46. No. 04)

Keratin hair treatments straighten, smooth, and add shine—though formaldehyde risks raise safety concerns for dermatologists and salon professionals.

QRPs are key to dermatologists' retirement plans—learn the benefits, drawbacks, and how to choose the best strategy for your financial goals.

From our April issue: Unlock exclusive AAD 2025 insights from top dermatology experts—what you missed and what’s next.

Tapinarof offers sustained relief for atopic dermatitis, enabling treatment-free periods and long-term disease control—even in young children.

Facial hyperpigmentation may signal systemic disease. Dermatologists must assess beyond melasma to ensure timely, accurate diagnosis and care.

Experts explore how rosacea research is evolving, with new treatments, gaps in care, and a push for more inclusive, targeted approaches.

Menopausal acne is rising yet underexplored; treatment must address hormonal shifts, skin sensitivity, and patient emotional well-being.

Bill Damsky, MD, PhD, pioneers molecular diagnostics to close the gap between research and clinical care in inflammatory skin disease.

Raj Chovatiya, MD, PhD, MSCI, explores case-based approaches to managing atopic dermatitis, focusing on treatment strategies, challenges, and clinical insights for improving patient outcomes.

Dermatology Times' Editor in Chief Christopher Bunick, MD, PhD, discusses patient safety in the wake of AAD 2025, focusing on BPO recalls, corticosteroid risks, and JAK inhibitor innovations.

Explore key takeaways from AAD 2025, rosacea insights, psoriasis updates, and expert interviews in the latest issue of Dermatology Times.

This review of the latest dermatologic studies includes insights into supporting laser tattoo removal for adults impacted by the justice-system, a case of blastic plasmacytoid dendritic cell neoplasm, and more.

Findings suggest that most patients on risankizumab met or exceeded the National Psoriasis Foundation’s treatment goals.

Shawn Kwatra, MD, FAAD, reviews his late-breaking data presentation at AAD on the first original studies of a topical cream for prurigo nodularis.

At AAAAI/WAO 2025, Bernstein explored new findings on rilzabrutinib and dupilumab in CSU, highlighting treatment gaps and future therapies.

In a conversation with Kristy Hamilton, MD, FACS, she spoke about the recent aesthetic trend and how clinicians can align with new patient expectations.

Dobkin underwent the procedure in order to connect with his patients considering it for themselves.